Delta inulin polysaccharide adjuvant enhances the ability of split-virion H5N1 vaccine to protect against lethal challenge in ferrets

Vaccine

Volumn 29, Issue 37, 2011, Pages 6242-6251

  Layton, R Colby ^a   Petrovsky, Nikolai ^b,c   Gigliotti, Andrew P ^a   Pollock, Zemmie ^a   Knight, Jennifer ^a   Donart, Nathaniel ^a   Pyles, John ^a   Harrod, Kevin S ^a   Gao, Peng ^a   Koster, Frederick ^a,b  

^a LOVELACE RESPIRATORY RESEARCH INSTITUTE   (United States)

^b FLINDERS UNIVERSITY   (Australia)

^c VAXINE PTY LTD   (Australia)

Author keywords

Adjuvant; Ferret; Influenza; Vaccine

Indexed keywords

ADVAX; DELTA INULIN; INFLUENZA VACCINE; INULIN; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOPENIA; DRUG EFFICACY; FERRET; HISTOPATHOLOGY; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; INFLUENZA VIRUS A H5N1; MORBIDITY; MORTALITY; NONHUMAN; PRIORITY JOURNAL; SURVIVAL; VIRION; VIRUS LOAD; WEIGHT REDUCTION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; FERRETS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; IMMUNIZATION, SECONDARY; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INULIN; ORTHOMYXOVIRIDAE INFECTIONS; VIRAL LOAD;

EID: 80051553818     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.06.078     Document Type: Article

References (50)

1. Lebarbenchon C., Feare C.J., Renaud F., Thomas F., Gauthier-Clerc M. Persistence of highly pathogenic avian influenza viruses in natural ecosystems. Emerg Infect Dis 2010, 16:1057-1062.
2. Hampson A.W. Ferrets and the challenges of H5N1 vaccine formulation. J Infect Dis 2006, 194:143-145.
3. Stephenson I., Gust I., Kieny M.P., Pervikov Y. Development and evaluation of influenza pandemic vaccines. Lancet Infect Dis 2006, 6:71-72.
4. Subbarao K., Joseph T. Scientific barriers to developing vaccines against avian influenza viruses. Nat Rev Immunol 2007, 7:267-278.
5. Saville M., Marsh G., Hoffenbach A. Improving seasonal and pandemic influenza vaccines. Influenza Other Respir Viruses 2008, 2:229-235.
6. Palache B. New vaccine approaches for seasonal and pandemic influenza. Vaccine 2008, 26:6232-6236.
7. Riley S., Wu J.T., Leung G.M. Optimizing the dose of pre-pandemic influenza vaccines to reduce the infection attack rate. PLoS Med 2007, 4:e218.
8. Gerhard W. The role of the antibody response in influenza virus infection. Curr Top Microbiol Immunol 2001, 260:171-190.
9. Hoffmann E., Lipatov A.S., Webby R.J., Govorkova E.A., Webster R.G. Role of specific hemagglutinin amino acids in the immunogenicity and protection of H5N1 influenza virus vaccines. Proc Natl Acad Sci U S A 2005, 102:12915-12920.
10. Baras Bt, Stittelaar K.J., Simon J.H., Thoolen R.J.M.M., Mossman S.P., Pistoor F.H., et al. Cross-protection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccine. PLoS One 2008, 3:e1401.
11. Middleton D., Rockman S., Pearse M., Barr I., Lowther S., Klippel J., et al. Evaluation of vaccines for H5N1 influenza virus in ferrets reveals the potential for protective single-shot immunization. J Virol 2009, 83:7770-7778.
12. Ruat C., Caillet C., Bidaut A., Simon J., Osterhaus A.D. Vaccination of macaques with adjuvanted formalin-inactivated influenza A virus (H5N1) vaccines: protection against H5N1 challenge without disease enhancement. J Virol 2008, 82:2565-2569.
13. Treanor J.J., Campbell J.D., Zangwill K.M., Rowe T., Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 2006, 354:1343-1351.
14. Chotpitayasunondh T., Thisyakorn U., Pancharoen C., Pepin S., Nougarede N. Safety, humoral and cell mediated immune responses to two formulations of an inactivated, split-virion influenza A/H5N1 vaccine in children. PLoS One 2008, 3:e4028.
15. Zangwill K.M., Treanor J.J., Campbell J.D., Noah D.L., Ryea J. Evaluation of the safety and immunogenicity of a booster (third) dose of inactivated subvirion H5N1 influenza vaccine in humans. J Infect Dis 2008, 197:580-583.
16. Nolan T., Richmond P.C., Formica N.T., Hoschler K., Skeljo M.V., Stoney T., et al. Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children. Vaccine 2008, 26:6383-6391.
17. Krewski D., Yokel R.A., Nierboer E., Borchelt D., Cohen J., Harry J., et al. Human health risk assessment for aluminum, aluminum oxide, and aluminum hydroxide. J Toxicol Environ Health B Crit Rev 2007, 10:1-269.
18. Silva D.G., Cooper P.D., Petrovsky N. Inulin-derived adjuvants promote both Th1 and Th2 immune responses. Immunol Cell Biol 2004, 82:611-616.
19. Petrovsky N. Novel human polysaccharide adjuvants with dual Th1 and th2 potentiating activity. Vaccine 2006, 24S2. S2/26-S22/29.
20. Petrovsky N. Freeing vaccine adjuvants from dangerous immunological dogma. Exper Rev Vaccines 2008, 7:7-10.
21. Cooper P.D., Steele E.J. The adjuvanticity of gamma inulin. Immunol Cell Biol 1988, 66:345-352.
22. Cooper P.D., Petrovsky N. Delta inulin: a novel, immunologically-active, stable packing structure comprising β-d-[2→1]poly(fructo-furanosyl) α-d-glucose polymers. Glycobiology 2010, [pub online 7 December, 2010].
23. Lobigs M., Pavy M., Hall R.A., Lobigs P., Cooper P., Komiya T., et al. An inactivated vero cell-grown Japanese encephalitis vaccine formulated with Advax, a novel inulin-based adjuvant, induces protective neutralizing antibody against homologous and heterologous flaviviruses. J Gen Virol 2010, 91:1407-1417.
24. Cristillo A.D., Grazia Ferrari M., Hudacik L., Lewis B., Galmin L., Bowen B., et al. Induction of mucos al and systemic antibody and T-cell responses following prime-boost immunization with novel adjuvanted human immunodeficiency virus-1-vaccine formulations. J Gen Virol 2011, 92:128-140.
25. Szretter K.J., Balish A.L., Katz J.M. Influenza: propagation, quantification, and storage. Curr Protoc Microbiol 2006, [chapter 15; unit 15G 11].
26. Harmon M.W., Rota P.A., Walls H.H., Kendal A.P. Antibody response in humans to influenza virus type B host-cell-derived variants after vaccination with standard (egg-derived) vaccine or natural infection. J Clin Microbiol 1988, 26:333-337.
27. Rowe T., Abernathy R.A., Hu-Primmer J., Thompson W.W., Lu X., Lim W., et al. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol 1999, 37:937-943.
28. Kayali G., Setterquist S.F., Capuano A.W., Myers K.P., Gill J.S., Gray G.C., et al. Testing human sera for antibodies against avian influenza viruses: horse RBC hemagglutination inhibition vs. microneutralization assays. J Clin Virol 2008, 43:73-78.
29. Layton R.C., Gigliotti A., Armijo P., Myers L., Knight J., Donart N., et al. Enhanced immunogenicity, mortality protection, and reduced viral brain invasion by alum adjuvant with an H5N1 split-virion vaccine in the ferret. PLoS One 2011, 8:e20641. http://dx.plos.org/10.1371/journal.pone.0020641.
30. Maher J.A., DeStefano J. The ferret: an animal model to study influenza virus. Lab Anim (NY) 2004, 33:50-53.
31. Tripp R.A., Tompkins S.M. Animal models for evaluation of influenza vaccines. Curr Top Microbiol Immunol 2009, 333:397-412.
32. Belser J.A., Szretter K.J., Katz J.M., Tumpey T.M. Use of animal models to understand the pandemic potential of highly pathogenic avian influenza viruses. Adv Virus Res 2009, 73:55-97.
33. Maines T.R., Chen L.M., Matsuoka Y., Chen H., Rowe T., Ortin J., et al. Lack of transmission of H5N1 avian-human reassortant influenza viruses in a ferret model. Proc Natl Acad Sci U S A 2006, 103:12121-12126.
34. Nicholson K.G., Colegate A.E., Podda A., Stephenson I., Wood J., Ypma E., et al. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 2001, 357:1937-1943.
35. Leroux-Roels I., Borkowski A., Vanwolleghem T., Drame M., Clement F., Hons E., et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 2007, 370:580-589.
36. Tripp R.A., Tompkins S.M. Recombinant vaccines for influenza virus. Curr Opin Investig Drugs 2008, 9:836-845.
37. Atmar R.L., Keitel W.A. Adjuvants for pandemic influenza vaccines. Curr Top Microbiol Immunol 2009, 333:323-344.
38. Bresson J.L., Perronne C., Launay O., Gerdil C., Saville M., Wood J., et al. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 2006, 367:1657-1664.
39. Keitel W.A., Campbell J.D., Treanor J.J., Walter E.B., Patel S.M., He F., et al. Safety and immunogenicity of an inactivated influenza A/H5N1 vaccine given with or without aluminum hydroxide to healthy adults: results of a phase I-II randomized clinical trial. J Infect Dis 2008, 198:1309-1316.
40. Brady R.C., Treanor J.J., Atmar R.L., Keitel W.A., Edelman R., Chen W.H., et al. Safety and immunogenicity of a subvirion inactivated influenza A/H5N1 vaccine with or without aluminum hydroxide among healthy elderly adults. Vaccine 2009, 27:5091-5095.
41. Bernstein D.I., Edwards K.M., Dekker C.L., Belshe R., Talbot H.K., Graham I.L., et al. Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults. J Infect Dis 2008, 197:667-675.
42. Forrest H.L., Khalenkov A.M., Govorkova E.A., Kim J.-K., Del Giudice G., Webster R.G. Single- and multiple-clade influenza A H5N1 vaccines induce cross protection in ferrets. Vaccine 2009, 27:4187-4195.
43. Keitel W., Groth N., Lattanzi M., Praus M., Hilbert A.K., Borkowski A., et al. Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1/2 clinical trial. Vaccine 2010, 28:840-848.
44. Clark T.W., Pareek M., Hoschler K., Dillon H., Nicholson K.G., Groth N., et al. Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. New Engl J Med 2009, 361:2424-2435.
45. Webby R.J., Andreansky S., Stambas J., Rehg J.E., Webster R.G., Doherty P.C., et al. Protection and compensation in the influenza virus-specific CD8+ T cell response. Proc Natl Acad Sci U S A 2003, 100:7235-7240.
46. Lipatov A.S., Hoffmann E., Salomon R., Yen H.L., Webster R.G. Cross-protectiveness and immunogenicity of influenza A/Duck/Singapore/3/97(H5) vaccines against Infection with A/Vietnam/1203/04(H5N1) virus in ferrets. J Infect Dis 2006, 194:1040-1043.
47. Miao H., Hollenbaugh J., Zand M., Holden-Wiltse J., Mosmann T.R., Perelson A.S., et al. Quantifying the early immune response and adaptive immune response kinetics in mice infected with influenza A virus. J Virol 2010, 84:6687-6698.
48. Layton R.C., Armijo P., Myers L., Knight J., Donart N., Sannes-Lowery K., et al. Ferret model of avian influenza demonstrates dose and strain dependant pathology and viral load in brain. Procedia Vaccinol 2009, 1:30-34.
49. Govorkova E.A., Webby R.J., Humberd J., Seiler J.P., Webster R.G. Immunization with reverse genetics produced H5N1 influenza vaccine protects ferrets against homologous and heterologous challenge. J Infect Dis 2006, 194:159-167.
50. Shinya K., Makino A., Hatta M., Watanabe S., Kim J.H., Hatta Y., et al. Subclinical brain injury caused by H5N1 influenza virus infection. J Virol 2011, 85:5202-5207.